ArticleTherapy (London, England : 2004)2011
Immunotherapy as a strategy for the treatment of non-small-cell lung cancer.
Article in Therapy (London, England : 2004), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis.BMJ open · 2015Pooled it
- Pooled it
- Strengths and weaknesses of immunotherapy for advanced non-small-cell lung cancer: a meta-analysis of 12 randomized controlled trials.PloS one · 2012Pooled it
- ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid Tumors.Cancers · 2023Article
- Review
- Detection of Potential Mutated Genes Associated with Common Immunotherapy Biomarkers in Non-Small-Cell Lung Cancer Patients.Current oncology (Toronto, Ont.) · 2022Article
- Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment.Frontiers in oncology · 2022Review
- Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer.Life (Basel, Switzerland) · 2021Review
- Recent Advances in Photodynamic Therapy for Deep-Seated Tumors with the Aid of Nanomedicine.Biomedicines · 2021Review
- Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.Thoracic cancer · 2020Article
- Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors.Cancers · 2018Review
- Antigen presentation of the Oct4 and Sox2 peptides by CD154-activated B lymphocytes enhances the killing effect of cytotoxic T lymphocytes on tumor stem-like cells derived from cisplatin-resistant lung cancer cells.Journal of Cancer · 2018Article
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.The Lancet. Oncology · 2017Review
- Adjuvant immunotherapy in resected early non-small cell lung cancer-battle lost, hopefully not the war!Journal of thoracic disease · 2016Article
- Specific immunotherapy generates CD8(+) CD196(+) T cells to suppress lung cancer growth in mice.Immunologic research · 2016Article
- Immature myeloid cells and tolerogenic cytokine profile in lung adenocarcinoma metastatic lymph nodes assessed by endobronchial ultrasound.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Combining radiation and immunotherapy: a new systemic therapy for solid tumors?Cancer immunology research · 2014Review
- Immunotherapy in lung cancer.Translational lung cancer research · 2014Review
- Immunotherapy in lung cancer.Translational lung cancer research · 2014Review
- Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Positive modulation of a patient's immune system to produce antitumor immunity is an attractive strategy that may improve the dismal outcomes typically associated with non-small-cell lung cancer (NSCLC). Using methods that either augment specific antitumor immunity or positively influence the patient's immune system to allow the de novo generation of immunity to encompass current strategies used in recent clinical trials of NSCLC. Encouraging results of Phase II trials in antigen-specific immunotherapy have led to three subsequent Phase III trials, which are currently enrolling. Results of these trials will improve our understanding of the role that immunotherapy plays in the treatment of NSCLC. Successful application of a humoral vaccine in Cuba led to its approval for the treatment of advanced NSCLC patients in that country. To date, trials involving nonspecific immunotherapeutic interventions have failed to improve outcomes in NSCLC and may indicate a need to combine them with antigen-specific vaccines. Although these trials will greatly advance our knowledge of NSCLC immunotherapy, we believe truly efficacious immunotherapy may only result from implementation of strategies to both augment antitumor immunity and counteract tumor-mediated immunosuppression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.